Sutro Biopharma Inc (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company in the United States, has named Shalini Sharp as its new director.
Sharp was chief financial officer and executive vice president of Ultragenyx Pharmaceutical Inc. She brings more than 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. She has been chief financial officer at Ultragenyx Pharmaceutical Inc. Prior to this role, she was chief financial officer at Agenus Inc. She is a member of the board of directors of Array BioPharma Inc. She is also a member of the board of directors of the TB Alliance, a non-profit organisation advancing the development and distribution of tuberculosis treatments in the developing world. Before joining Agenus Inc., she worked in corporate strategy and corporate development at Elan Pharmaceuticals plc, was a management consultant at McKinsey & Company, and was an investment banker at Goldman Sachs, always specialising in pharmaceuticals and medical devices.
Bill Newell, Sutro's chief executive officer, said, 'Ms Sharp arrives at a key time for the company as we continue to fortify our leadership and board team with accomplished individuals well-versed in the life sciences industry. Her expertise and background are an ideal complement to our board of directors. We believe her financial and strategic guidance will be of great value to Sutro as we drive forward our internal and collaborative efforts to develop next-generation cancer therapeutics.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business